A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate.
Novel cancer therapy
bladder cancer
low toxicity
peptide-oleate complex
protein folding
Journal
Molecular & cellular oncology
ISSN: 2372-3556
Titre abrégé: Mol Cell Oncol
Pays: United States
ID NLM: 101642411
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
12
2021
Statut:
epublish
Résumé
The protein-lipid complex alpha1-oleate, derived from HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), is identified as a molecular entity with significant therapeutic potential. Structural characterization of the complex and results of a successful placebo-controlled clinical trial are presented.
Identifiants
pubmed: 34859140
doi: 10.1080/23723556.2021.1974278
pii: 1974278
pmc: PMC8632289
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1974278Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
C.S. holds shares in HAMLET Pharma, as a representative of scientists in the HAMLET group. Patents protecting the use of the alpha1-oleate complex have been granted. Other authors declare no conflict of interest.
Références
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8064-8
pubmed: 7644538
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
J Mol Biol. 2009 Dec 18;394(5):994-1010
pubmed: 19766653
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Sci Rep. 2015 Nov 12;5:16432
pubmed: 26561036
Oncogene. 2016 Feb 18;35(7):897-907
pubmed: 26028028
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4221-6
pubmed: 10760289
Nat Commun. 2021 Jun 8;12(1):3427
pubmed: 34103518
N Engl J Med. 2004 Jun 24;350(26):2663-72
pubmed: 15215482
Int J Cancer. 2020 Nov 1;147(9):2479-2492
pubmed: 32319672